Arvinas, Inc. (ARVN) compared with its closest peers (SNSE, CTNM, CBIO, CRMD, VSTM): P/E 65.9 vs industry 17.2. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Sensei Biotherapeutics, Inc. (SNSE) | $670.82M | -0.7 |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $644.07M | -5.3 |
| Crescent Biopharma, Inc. (CBIO) | $638.50M | — |
| CorMedix Inc. (CRMD) | $638.36M | 3.4 |
| Verastem, Inc. (VSTM) | $605.45M | -2.6 |
| Altimmune, Inc. (ALT) | $602.87M | -3.6 |
| Aquestive Therapeutics, Inc. (AQST) | $583.63M | -8.4 |
| Shattuck Labs, Inc. (STTK) | $578.55M | -5.2 |
| Evolus, Inc. (EOLS) | $554.49M | -8.3 |
| ARS Pharmaceuticals, Inc. (SPRY) | $546.17M | -6.7 |
| Stock P/E | 65.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 203.1% |
| vs Industry | 283.6% |
ARVN overview · ARVN earnings · ARVN financials · ARVN KPIs · ARVN investor relations · ARVN ownership · ARVN filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.